Bromhexine hydrochloride

Category	SARS-CoV
CAS	611-75-6
Description	Bromhexine is a mucolytic (expectorant) agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties.

Quotation Now

Product Information

Synonyms	Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-, hydrochloride (1:1); Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-, monohydrochloride; Toluene-α,2-diamine, 3,5-dibromo-Nα-cyclohexyl-Nα-methyl-, monohydrochloride; 2,4-Dibromo-6-[(cyclohexyl-methyl-amino)-methyl]-phenylamine hydrochloride; 2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine monohydrochloride; Auxit; Bisolvon; Bisolvon hydrochloride; Bromhexine chloride; Bromhexine monohydrochloride; Cyclohexylmethyl(2-amino-3,5-dibromobenzyl)ammonium chloride; N-Cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)ammonium chloride; N-Cyclohexyl-N-methyl-N-(2-amino-3,5-dibromobenzyl)ammonium chloride; Nα-Cyclohexyl-Nα-methyl-3,5-dibromotoluene-α,2-diamine hydrochloride; Ophtosol; Quentan
IUPAC Name	2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;hydrochloride
Molecular Weight	412.59
Molecular Formula	C14H20Br2N2.HCl
Canonical SMILES	CN(CC1=CC(=CC(=C1N)Br)Br)C2CCCCC2.Cl
InChI	InChI=1S/C14H20Br2N2.ClH/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17;/h7-8,12H,2-6,9,17H2,1H3;1H
InChIKey	UCDKONUHZNTQPY-UHFFFAOYSA-N
Boiling Point	441.5±35.0°C at 760 mmHg
Melting Point	237.5-289°C (dec.)
Flash Point	220.8°C
Purity	≥95%
Density	N/A
Solubility	Soluble in Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
Appearance	White to Light Beige Solid
Storage	Store at 2-8°C
Complexity	256
Exact Mass	411.97395
In Vitro	Bromhexine hydrochloride (BHH; 250 μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells. Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.
In Vivo	Bromhexine hydrochloride (30mg/kg; ip; three times per week for 5 weeks) significantly reduces the incidence of distant metastasis to lung and liver sites from 55% in vehicle-treated animals to 20% in Wild-type C57BL/6 and TRAMP mice with PIN (prostatic intraepithelial neoplasia). The prostate glands of the mice treated with Bromhexine hydrochloride are generally substantially larger than vehicle-treated TRAMP mice.
PSA	29.26000
Target	SARS-CoV; Autophagy; HIV-1